ABBV · Abbvie Inc
United States · RS rating 93 · As of 2026-11-03
| Price | 286.00 USD |
|---|---|
| 1-day change | -1.0% |
| RS rating (overall / 1M / 3M / 12M) | 93 / 79 / 88 / 78 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 53 / 77 / 55 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | +920.0% |
| Sales growth Q/Q | +5.3% |
| Distance from 52-week high | +3.0% |
| Market cap (USD) | $355.4B |